Skip to main content
. 2023 Jun 2;13(7):1611–1615. doi: 10.1007/s13555-023-00940-0

Fig. 2.

Fig. 2

Hidradenitis suppurativa lesions in the right axillary region of the patient after 40 weeks of treatment with tildrakizumab